DK2535716T3 - Cancer marker and therapeutic target - Google Patents

Cancer marker and therapeutic target Download PDF

Info

Publication number
DK2535716T3
DK2535716T3 DK12183760.3T DK12183760T DK2535716T3 DK 2535716 T3 DK2535716 T3 DK 2535716T3 DK 12183760 T DK12183760 T DK 12183760T DK 2535716 T3 DK2535716 T3 DK 2535716T3
Authority
DK
Denmark
Prior art keywords
ccr4
cancer
cells
ccl17
tumor
Prior art date
Application number
DK12183760.3T
Other languages
Danish (da)
English (en)
Inventor
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Frances Balkwill
Original Assignee
Cancer Res Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2535716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Res Tech Ltd filed Critical Cancer Res Tech Ltd
Application granted granted Critical
Publication of DK2535716T3 publication Critical patent/DK2535716T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
DK12183760.3T 2007-09-18 2008-09-18 Cancer marker and therapeutic target DK2535716T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
EP08806315.1A EP2176664B1 (en) 2007-09-18 2008-09-18 Ccr4 as cancer marker

Publications (1)

Publication Number Publication Date
DK2535716T3 true DK2535716T3 (en) 2017-02-13

Family

ID=38670078

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12183760.3T DK2535716T3 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
DK12182790.1T DK2533047T3 (en) 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer
DK08806315.1T DK2176664T3 (da) 2007-09-18 2008-09-18 Ccr4 som cancermarkør

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK12182790.1T DK2533047T3 (en) 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer
DK08806315.1T DK2176664T3 (da) 2007-09-18 2008-09-18 Ccr4 som cancermarkør

Country Status (11)

Country Link
US (2) US9134293B2 (https=)
EP (3) EP2533047B1 (https=)
JP (2) JP5774309B2 (https=)
AU (1) AU2008300413B2 (https=)
CA (1) CA2699702C (https=)
DK (3) DK2535716T3 (https=)
ES (3) ES2588507T3 (https=)
GB (1) GB0718167D0 (https=)
PL (3) PL2176664T3 (https=)
RU (2) RU2529797C2 (https=)
WO (1) WO2009037454A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011157678A1 (en) * 2010-06-14 2011-12-22 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
EP2771488B1 (en) 2011-10-24 2018-03-28 SignalChem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
BR112014013138B1 (pt) 2011-12-01 2022-06-28 Chemocentryx, Inc Compostos de anilinas substituídas como antagonistas de ccr(4) e composição farmacêutica compreendendo os mesmos
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
EP3065774B1 (en) * 2013-11-06 2021-05-26 Janssen Biotech, Inc. Anti-ccl17 antibodies
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
WO2016050904A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
EP3283886B1 (en) * 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
CN110603056A (zh) * 2017-05-19 2019-12-20 日本全药工业株式会社 基于ccr4阻断的调节性t细胞浸润抑制方法及犬的肿瘤性疾病的治疗方法
KR102817790B1 (ko) 2018-08-29 2025-06-05 케모센트릭스, 인크. C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
US20020132836A1 (en) 2000-10-11 2002-09-19 Chemocentryx Inc. Compounds and methods for modulating CCR4 function
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
SI1326617T1 (sl) 2000-10-18 2007-02-28 Schering Ag Uporaba 11 beta-(4-acetilfenil)-17 beta-hidroksi-17 alfa-(1,1,2,2,2-pentafluoroetil)estra-4,9-dien-3-ona za pripravo zdravila za zdravljenje raka dojk, raka jajcnikov, endometrijskega raka, mieloma in meningioma
CA2439279A1 (en) * 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2003014153A2 (en) 2001-08-10 2003-02-20 Topigen Pharmaceutique Inc. Cellular virus receptors and methods of use.
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
EP1688436A4 (en) * 2003-10-08 2009-12-02 Kyowa Hakko Kirin Co Ltd ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY
JPWO2005053741A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
DK2135949T3 (da) 2006-02-14 2013-02-04 Noxxon Pharma Ag MCP-1-bindende nukleinsyrer
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
US9134293B2 (en) 2015-09-15
PL2176664T3 (pl) 2014-04-30
EP2533047B1 (en) 2016-05-11
US10261099B2 (en) 2019-04-16
CA2699702A1 (en) 2009-03-26
PL2535716T3 (pl) 2017-06-30
RU2529797C2 (ru) 2014-09-27
EP2533047A1 (en) 2012-12-12
ES2588507T3 (es) 2016-11-03
JP2010539508A (ja) 2010-12-16
DK2176664T3 (da) 2014-01-20
US20100278844A1 (en) 2010-11-04
WO2009037454A2 (en) 2009-03-26
EP2535716A2 (en) 2012-12-19
GB0718167D0 (en) 2007-10-31
JP2015212703A (ja) 2015-11-26
AU2008300413A1 (en) 2009-03-26
DK2533047T3 (en) 2016-08-22
RU2010123921A (ru) 2011-12-20
EP2176664A2 (en) 2010-04-21
PL2533047T3 (pl) 2016-11-30
EP2535716A3 (en) 2013-03-13
JP5774309B2 (ja) 2015-09-09
EP2535716B1 (en) 2016-11-02
RU2014128513A (ru) 2016-02-10
WO2009037454A3 (en) 2009-05-07
AU2008300413B2 (en) 2014-09-11
US20160223572A1 (en) 2016-08-04
EP2176664B1 (en) 2013-11-06
JP6234967B2 (ja) 2017-11-22
ES2612690T3 (es) 2017-05-18
CA2699702C (en) 2018-03-06
ES2443541T3 (es) 2014-02-19

Similar Documents

Publication Publication Date Title
DK2535716T3 (en) Cancer marker and therapeutic target
JP5795311B2 (ja) 抗体ベースのアレイを使用する胃癌療法のための薬物選択
Ren et al. Intratumoral CD103+ CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
MX2010009140A (es) Seleccion de farmacos para terapia de cancer de mama utilizando matrices basadas en anticuerpos.
JP2013520958A (ja) 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法
CN102667484A (zh) 识别黑素瘤肿瘤细胞的生物标记
EP2805166B1 (en) Method for the prognosis of survival time of a patient suffering from a solid cancer
Kim et al. B7-H3 and B7-H4 expression in breast cancer and their association with clinicopathological variables and T cell infiltration
Wang et al. Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer
JP2020040959A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
Hermida-Prado et al. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Shu et al. Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade
Dubuisson et al. Immunodynamics of explanted human tumors for immuno‐oncology
CN116137862A (zh) 三级淋巴结构在预后疾病进展和治疗癌症中的应用
AU2013203349B2 (en) Cancer marker and therapeutic target
Zhu et al. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells
JP2019518970A (ja) 腎臓癌を患う対象の癌治療に対する感受性を予測するための方法およびキット
Yang Upregulation of CD112R (PVRIG) and PD-1 on cytotoxic T-cells located in T-cell niche of colorectal cancer
Anders et al. ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes
Nakajima et al. Immune landscape of neoadjuvant chemoradiotherapy: involvement of MAL, a T-cell differentiation protein
Gouravski Assessing ER Positive Breast Cancer Heterogeneity and Identification of Tumour Microenvironment Molecular Markers in Response to Treatment Via Multi-omic Approach
TW202417641A (zh) 預測對egfr激酶活性之抑制劑的反應之方法
Musrap Proteomic Identification of Mediators Implicated in the Metastatic Progression of Ovarian Cancer